- Guideline-concordant chemotherapy is of no to minimal survival benefit for patients ≥70 years with hormone receptor (HR)-positive, node-positive invasive early breast cancer, according to a cohort study from Germany.
- Across patients of all ages, there was an OS and distant metastasis-free benefit (DMFS).
Why this matters
- Older patients should be informed of the minimal benefit weighed against the risks of chemotherapy.
- Population-based, retrospective cohort from Regensburg, Germany, comparing patients who received S3 Guideline-concordant chemotherapy (n=1544) vs no chemotherapy (n=228).
- Funding: None disclosed.
- Median follow-up, 6.4 years.
- Across all ages, chemotherapy was associated with better 5-year OS (91.3% after chemotherapy vs 76.8% after no chemotherapy; P<.001 and dmfs vs respectively p>
- Subgroup analysis of patients ≥70 years found that chemotherapy was associated with minimally better 5-year OS (75.4% vs 72.6%; P=.038), but no better DMFS (74.0% vs 71.4%; P=.112).
- Subgroup analysis of patients
- Missing information on nononcological comorbidities.